The effects of melatonin against atherosclerosis-induced endothelial dysfunction and inflammation in hypercholesterolemic rats

Sezgin, Dilşad; Aslan, Gülnur; Şahin, Kazım; Tuzcu, Mehmet; İlhan, Necip; Şahna, Engin

doi:10.1080/13813455.2020.1838550

Cited by 11 publications

(3 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The result of our study is different from that reported by Ismail and Mahmood (2022) who found that there was a highly significant difference and variability bout changes in lipid profiles in melatonin group than without melatonin group and this difference may be due to that this study was shorter than our study, and further they used streptozotocin-induced rat while we used atherosclerosis induced rabbits [14]. Furthermore, it has recently been discovered that while melatonin has no effect on total cholesterol, it greatly increases the serum triglyceride and HDL-C level [15,16].…”

Section: Resultsmentioning

confidence: 59%

Untitled

2023

J. Med. Chem. Sci.

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 59%

Untitled

2023

J. Med. Chem. Sci.

View full text Add to dashboard Cite

“…Melatonin has been shown to ameliorate ED in animal models of hypercholesterolemia and DM by regulating NO availability and inflammatory pathways; 18 , 19 , 20 however, clinical trials results are inconsistent in this regard. In a randomized clinical trial, 1 month of 10 mg oral melatonin was found to reduce serum markers of ED and increase serum NO levels in patients with severe CAD.…”

Section: Discussionmentioning

confidence: 99%

Effect of melatonin supplementation on endothelial function in heart failure with reduced ejection fraction: A randomized, double‐blinded clinical trial

Hoseini

Heshmat-Ghahdarijani

Khosrawi

et al. 2021

Clinical Cardiology

View full text Add to dashboard Cite

Background This study aimed to investigate the effect of melatonin supplementation on endothelial function in patients with heart failure with reduced ejection fraction (HFrEF). Methods This is an analysis of the MeHR trial, a randomized double‐blinded placebo‐controlled clinical trial with two parallel arms of 1:1. Oral 10 mg melatonin tablets or placebo was administered for 24 weeks. Deference in the percentage of flow‐mediated dilatation (FMD) after the intervention was the primary outcome. Results Ninety‐two patients were included in the study (age: 62.7±10.3 years, 87.0% male, ejection fraction (EF): 28.6±8.1). After adjustment for baseline FMD and age, a statistically significant difference in post‐treatment FMD in favor of the melatonin group was seen (estimated marginal means [95%CI], melatonin: 7.84% [6.69–8.98], placebo: 5.98% [4.84–7.12], p = .027). There was no significant difference in the mean of post‐treatment systolic/diastolic blood pressure, serum total antioxidant capacity, and serum malondialdehyde (MDA) between groups. Subgroup analysis showed significant improvement in FMD and MDA in the melatonin group in nondiabetic patients, while no difference was seen between study groups in diabetic patients. Conclusions Melatonin supplementation in HFrEF might improve endothelial function; however, this beneficial effect might not be seen in diabetic patients.

show abstract

“…MAPK signaling pathways (Zhang J. et al, 2020). Melatonin may have protective and therapeutic effects on hypercholesterolemia by regulating vaspin, STAT-3, DDAH, and ADMA signaling pathways (Sezgin et al, 2020). Increased levels of STAT-1 promote SMC (Smooth muscle cell) de-differentiation, whereas high levels of STAT-3 drive SMC into a more mature phenotype (Kirchmer et al, 2014).…”

Section: Jak/stat Pathway In Oncopathologymentioning

confidence: 99%

JAK/STAT pathway: Extracellular signals, diseases, immunity, and therapeutic regimens

Bian

Rong

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Janus kinase/signal transduction and transcription activation (JAK/STAT) pathways were originally thought to be intracellular signaling pathways that mediate cytokine signals in mammals. Existing studies show that the JAK/STAT pathway regulates the downstream signaling of numerous membrane proteins such as such as G-protein-associated receptors, integrins and so on. Mounting evidence shows that the JAK/STAT pathways play an important role in human disease pathology and pharmacological mechanism. The JAK/STAT pathways are related to aspects of all aspects of the immune system function, such as fighting infection, maintaining immune tolerance, strengthening barrier function, and cancer prevention, which are all important factors involved in immune response. In addition, the JAK/STAT pathways play an important role in extracellular mechanistic signaling and might be an important mediator of mechanistic signals that influence disease progression, immune environment. Therefore, it is important to understand the mechanism of the JAK/STAT pathways, which provides ideas for us to design more drugs targeting diseases based on the JAK/STAT pathway. In this review, we discuss the role of the JAK/STAT pathway in mechanistic signaling, disease progression, immune environment, and therapeutic targets.

show abstract

The effects of melatonin against atherosclerosis-induced endothelial dysfunction and inflammation in hypercholesterolemic rats

Cited by 11 publications

References 45 publications

Untitled

Untitled

Effect of melatonin supplementation on endothelial function in heart failure with reduced ejection fraction: A randomized, double‐blinded clinical trial

JAK/STAT pathway: Extracellular signals, diseases, immunity, and therapeutic regimens

Contact Info

Product

Resources

About